Available to laboratories of successful Principal Investigators
LifeArc, the medical research charity formerly known as MRC Technology, has launched the LifeArc Translational Award for academic scientists to progress early stage drug discovery projects. £100,000 will be awarded to the laboratory of each successful Principal Investigator (PI) to fund the development of novel small molecule or therapeutic antibody drug targets.
“LifeArc progresses promising early stage research with the aim of finding new treatments and diagnostics for diseases that present medical challenges,” said Dr John Kelly, Head of Business Development, Therapeutics and Diagnostics at LifeArc. “The new awards will allow us to identify research breakthroughs that can be translated in our own laboratories with our academic collaborator and partnered with industry to provide new treatments.”
The charity has dedicated laboratories in Stevenage and Edinburgh, where around 100 scientists work on drug discovery and diagnostic development projects. LifeArc Translational Awards will be made after the successful review of the project by LifeArc’s internal panel and diligence in its drug discovery labs.
So far LifeArc has humanised almost 60 antibodies and helped to develop four marketed drugs (Keytruda®, Actemra®, Tysabri® and Entyvio®) and a test for antibiotic resistance.
Earlier in the year LifeArc announced four therapeutic areas they are particularly interested in: antimicrobials, neuroscience, personalised oncology and respiratory diseases. Targets outside these areas will also be considered, as the charity supports medical breakthroughs where it perceives that they will provide a clear benefit to patients.
For further information and to find out how to apply, please visit https://www.lifearc.org/working-with-us/drug-discovery/
Notes to editors
Liezel Tipper, PR & Communications Manager, LifeArc. Tel: 020 7391 2772, Email: Liezel.Tipper@lifearc.org.
LifeArc is the new name for MRC Technology, a medical research charity with a 25 year legacy of helping scientists and organisations turn their research into treatments and diagnostics for patients.
The new name reflects the charity’s purpose: to be the arc or bridge between research and improving patients’ lives.
LifeArc is pioneering new ways to turn great science into greater patient impact. It brings together a network of partners to tackle specific diseases and directly funds academic and early stage research.
The charity has dedicated laboratories in Stevenage where around 80 scientists work on antibody and small molecule projects, while the Edinburgh lab progresses diagnostics development.
So far, LifeArc’s work has helped to develop four drugs (Keytruda®, Actemra®, Tysabri® and Entyvio®) and a test for antibiotic resistance.
www.lifearc.org Twitter @lifearc1